To further elucidate the mechanistic basis of TPST2 knock-down on enhancing anti-tumor immunity and the efficacy of anti-PD1 therapy, we performed RNA sequencing on residual tumor tissues from syngeneic mouse model (Fig. 4b). The gene discussed is TPST2; the disease is neoplasm.